How Much Weight Will You Lose on Wegovy? Honest Answers

The trial numbers: what 'average' actually means for you

A question our prescribers hear most weeks is some version of: "But will I get the average result, or less?" It's a fair thing to ask. The landmark STEP 1 trial, published in the New England Journal of Medicine, followed nearly 2,000 adults with obesity or overweight over 68 weeks. Those on semaglutide 2.4mg lost an average of around 15% body weight. Roughly a third lost 20% or more. A smaller group lost less than 5%.

Those aren't outliers at the fringes of a graph, they're real people, and they reflect something important: the "average" is a midpoint, not a promise. Your result sits somewhere on that distribution. Factors that shift where you land include how consistently you take the treatment, whether you make dietary changes alongside it, your starting metabolic profile, and whether your dose is titrated fully. The full picture of Wegovy weight loss covers the range in more detail.

The newer 7.2mg dose, approved by the MHRA in April 2026, produced an average of roughly 20.7% weight loss over 72 weeks in trials, approaching the results seen with tirzepatide. That's a meaningful step up, though it involves the same gradual titration and the same prescriber oversight. Results for the 7.2mg dose aren't yet as widely replicated as those for 2.4mg.

The factors your prescriber weighs before predicting anything

Asking how much weight you'll lose before a clinical assessment is a bit like asking how long a journey takes before you've given anyone your starting point. Your prescriber considers your current weight, BMI, any weight-related conditions, medication history and how you've responded to previous attempts at weight management. None of that is box-ticking, it directly shapes what dose is appropriate, how quickly you'll titrate, and what a realistic goal looks like for you specifically.

NICE's guidance, detailed in technology appraisal TA875, recommends reviewing whether to continue if less than 5% weight loss has been achieved after six months on the maintenance dose. That's a clinical checkpoint built into good practice, not a threat, it's one reason ongoing prescriber oversight matters rather than just starting and hoping.

Early doses like 0.25mg are titration steps, not therapeutic doses. You're unlikely to see significant weight change during the starter phase; the evidence relates to the maintenance dose. If you want to understand what to expect at 0.25mg specifically, that page sets realistic expectations for the early weeks. For those moving up through the dose schedule, our page on how much weight you might lose on 1mg of Wegovy gives a clearer sense of what to expect as titration progresses.

The cost decision: what you're actually paying for

Private Wegovy treatment in the UK is priced per four-week supply, and the honest answer is that prices vary considerably between providers. Following Eli Lilly's list price changes in September 2025, the broader GLP-1 market has seen upward pressure; if you want a straightforward breakdown of how much Wegovy will cost and what drives the variation between providers, that page pulls the figures together clearly.

What headline prices often leave out: consultation fees, prescription charges, delivery costs, and any ongoing dose-review support. A price that looks lower at first glance sometimes turns out to be the medicine only, with everything else charged separately. That's worth checking before you commit anywhere.

nume's position on this is straightforward: we're not trying to win on price. One transparent figure covers your consultation, your prescription, the treatment, free next-working-day delivery by DPD, and 7-day aftercare. No hidden charges, no subscription, no auto-renewal. Every repeat order gets a fresh clinical review, because a prescriber looking at how you're doing after 12 weeks should see a different conversation than the one at week one. Current treatment pricing is on the treatment page; you won't find it in the body of this article.

Why 'cheapest' is the wrong starting point for a prescription medicine

The amount of weight you lose on Wegovy is shaped partly by the quality of clinical oversight you receive alongside it. Dose titration, managing side effects, knowing when to pause and when to push on, these are clinical decisions, not automatic. A cheaper listing that skips proper assessment, or that can't tell you who reviewed your case or how, isn't actually a better deal. It's a different product.

The MHRA has issued clear warnings about counterfeit and illegally sold weight-loss pens circulating in the UK, including fake pens that have contained insulin rather than semaglutide. If a price is far below the market range, or a seller offers these medicines without requiring a clinical assessment, that's a red flag worth taking seriously. You can verify any online pharmacy on the GPhC register, our registration number is 9012878. For anyone comparing semaglutide to tirzepatide, the semaglutide results page and the Wegovy overview set out the differences clearly.

For more detail on what the treatment costs and what different providers typically include, the Wegovy strengths and prices page is a useful next stop.